Last reviewed · How we verify
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of IvabRadine hemisulfate Sustained-release Tablets versus placebo in patients with moderate to severe chronic systolic heart failure.
Details
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | UNKNOWN |
| Enrolment | 336 |
| Start date | 2014-05 |
Conditions
- Chronic Systolic Heart Failure
Interventions
- IvabRadine hemisulfate Sustained-release Tablets
- placebo
Primary outcomes
- Change From Baseline in Left Ventricular End Systolic Volume Index by ultrasound cardiogram — baseline and week 32
Countries
China